TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16286443

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1265

Group type: COMPARATOR
Intervention: CMAI factor structure
Number of subjects: 1265
Study: 12080437

Group type: EXPERIMENTAL
Intervention: Combination of Mediterranean diet and leisure time physical activity
Number of subjects: 848
Study: 10743730

Group type: EXPERIMENTAL
Intervention: Exercise training (ergometry or rapid walking) at 60-80% of maximal performance for 30 minutes once a day for 2 months
Number of subjects: 29
Study: 7628178

Group type: EXPERIMENTAL
Intervention: Oral ketoconazole
Number of subjects: 5
Study: 1771224

Group type: EXPERIMENTAL
Intervention: Atenolol (75 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lactate placebo
Number of subjects: 36
Study: 6787141

Group type: EXPERIMENTAL
Intervention: Parenteral hyperalimentation fluids
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Positive blood cultures for yeast
Number of subjects: 131

Group type: COMPARATOR
Intervention: No eye lesions
Number of subjects: 131
Study: 30579806

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks added to rosuvastatin 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care arm (rosuvastatin 10 mg/day, with initiation and/or dose adjustment of non-statin lipid-lowering to achieve an LDL-C target of <70 mg/dL)
Number of subjects: 0
Study: 28885317

Group type: COMPARATOR
Intervention: PLGA/HA/β-TCP
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PLGA/HA/β-TCP with 2.0% simvastatin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: DBBM-C
Number of subjects: 13

Group type: COMPARATOR
Intervention: Spontaneous healing (control)
Number of subjects: 13
Study: 25834412

Group type: EXPERIMENTAL
Intervention: Low-frequency low-intensity pulsed magnetic field (LFLIPMF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Circuit weight training (CWT)
Number of subjects: 30
Study: 23670660

Group type: EXPERIMENTAL
Intervention: Practice level training in a whole systems approach to self management support.
Number of subjects: 5599

Group type: COMPARATOR
Intervention: Control practices (no specific intervention mentioned).
Number of subjects: 5599
Study: 21419745

Group type: EXPERIMENTAL
Intervention: 7 mg/d MK-0736
Number of subjects: 54

Group type: COMPARATOR
Intervention: MK-0916
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 19263464

Group type: EXPERIMENTAL
Intervention: Active antidepressant groups
Number of subjects: 8385

Group type: COMPARATOR
Intervention: Placebo groups
Number of subjects: 8385

Group type: EXPERIMENTAL
Intervention: Baseline mean Hamilton Depression Rating Scale (HDRS)
Number of subjects: 8385

Group type: EXPERIMENTAL
Intervention: Sample size
Number of subjects: 8385

Group type: EXPERIMENTAL
Intervention: Treatment allocation
Number of subjects: 8385

Group type: EXPERIMENTAL
Intervention: Study duration
Number of subjects: 8385

Group type: EXPERIMENTAL
Intervention: Study location (USA)
Number of subjects: 8385
Study: 17723086

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasodilatory antihypertensives (renin-angiotensin-aldosterone system inhibitors and calcium channel blockers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15114089

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cyclosporine-ME
Number of subjects: 205
Study: 11405308

Group type: EXPERIMENTAL
Intervention: Reduced visual acuity through partial occlusion filters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced auditory acuity through headphone-shaped noise protectors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both visual and auditory acuity reductions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (not explicitly defined)
Number of subjects: 0
Study: 9885116

Group type: EXPERIMENTAL
Intervention: Factor XIII (2500 units postoperatively)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no Factor XIII administration)
Number of subjects: 22
Study: 7930743

Group type: EXPERIMENTAL
Intervention: Single-dose artesunate (4 mg/kg) plus mefloquine (25 mg of base/kg)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Three days of artesunate (total dose, 10 mg/kg) plus mefloquine (25 mg/kg)
Number of subjects: 652
Study: 2124724

Group type: EXPERIMENTAL
Intervention: 400-micrograms misoprostol tablets twice daily
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 426986

Group type: EXPERIMENTAL
Intervention: Dopamine 0.5‐6.0 microgram kg‐1 min‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Droperidol 0.25 mg kg‐1
Number of subjects: 0
Study: 31164153

Group type: EXPERIMENTAL
Intervention: Heel-unloading orthosis (Settner shoe)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment without the orthosis
Number of subjects: 0
Study: 28292202

Group type: EXPERIMENTAL
Intervention: Proso millet products (couscous, biscuit, extruded snack, porridge)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Corn products (couscous, biscuit, extruded snack, porridge)
Number of subjects: 12
Study: 25872390

Group type: EXPERIMENTAL
Intervention: NSAIDs (nepafenac)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SAIDs (dexamethasone)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination therapy (nepafenac and dexamethasone)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no preoperative therapy)
Number of subjects: 80
Study: 23963586

Group type: EXPERIMENTAL
Intervention: Advice to rest
Number of subjects: 52650

Group type: EXPERIMENTAL
Intervention: Seeing others with disabling LBP
Number of subjects: 52650

Group type: EXPERIMENTAL
Intervention: History of chronic LBP
Number of subjects: 52650

Group type: EXPERIMENTAL
Intervention: Radiating pain below the knee
Number of subjects: 52650

Group type: EXPERIMENTAL
Intervention: Workers' compensation
Number of subjects: 52650

Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 52650

Group type: EXPERIMENTAL
Intervention: LBP attributed to sports
Number of subjects: 52650
Study: 21241352

Group type: EXPERIMENTAL
Intervention: DCF100C 1.0%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DCF100C 2.5%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DCF100C 1.0% with menthol and eucalyptus oil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DCF100C 2.5% without sensory excipients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Voltaren Emulgel 1.0%
Number of subjects: 20
Study: 19827650

Group type: EXPERIMENTAL
Intervention: Rapamycin-eluting stents
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (group 2)
Number of subjects: 26
Study: 16949661

Group type: EXPERIMENTAL
Intervention: Permaquick applied with the stiff micro‐hybrid composite Amelogen Hybrid (PMQ/A‐Hy, Ultradent)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Permaquick applied with the more flexible micro‐filled composite Amelogen Microfill (PMQ/A‐Mi, Ultradent)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Optibond FL applied with the micro‐hybrid composite Prodigy (O‐FL/Pro, Kerr)
Number of subjects: 71
Study: 15497671

Group type: EXPERIMENTAL
Intervention: Test formulation (Ecrox) 25 mg rofecoxib tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (originator product) 25 mg rofecoxib tablet
Number of subjects: 24
Study: 11442183

Group type: EXPERIMENTAL
Intervention: Recorded instructions in patients' native language
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interpreter‐assisted instructions
Number of subjects: 60
Study: 9917607

Group type: EXPERIMENTAL
Intervention: Enhanced posterior soft tissue repair after total hip replacement
Number of subjects: 679

Group type: COMPARATOR
Intervention: Standard posterior approach to total hip replacement (before enhanced closure)
Number of subjects: 679
Study: 8113775

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 3186379

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (n = 8)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional ventilation (n = 5)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation and Conventional ventilation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Not bronchoscoped infants
Number of subjects: 40
Study: 1103765

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31164160

Group type: EXPERIMENTAL
Intervention: 2-year multimodal intervention (diet, exercise, cognitive training, vascular risk monitoring)
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: 2-year multimodal intervention
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Control (general health advice)
Number of subjects: 1260
Study: 28418808

Group type: EXPERIMENTAL
Intervention: Enriched margarine and rapeseed oil (MR)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Rapeseed oil (R)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Enriched margarine (M)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Olive oil control diet (O)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: MR group
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid and trans FA concentrations
Number of subjects: 76
Study: 26252316

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (blood pressure cuff inflated to 25 mm Hg)
Number of subjects: 80
Study: 23902673

Group type: EXPERIMENTAL
Intervention: Lupin protein isolate (LPI) 25 g/d
Number of subjects: 33

Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Lupin protein isolate (LPI) and Milk protein isolate (MPI)
Number of subjects: 33
Study: 21715698

Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy (3 months)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acute L-ascorbate alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: L-ascorbate combined with arginase inhibition
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (baseline in NC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (baseline in HC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ascorbate alone post-atorvastatin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ascorbate combined with arginase inhibition post-atorvastatin
Number of subjects: 18
Study: 19210493

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 1392

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 1392

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg
Number of subjects: 1392
Study: 16703434

Group type: EXPERIMENTAL
Intervention: Group A (2 mg/kg of bupivacaine in 200 ml of normal saline before creation of pneumoperitoneum)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group B (2 mg/kg of bupivacaine in 200 ml of normal saline after creation of pneumoperitoneum)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group C (200 ml of normal saline before creation of pneumoperitoneum)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group D (200 ml of normal saline after creation of pneumoperitoneum)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group C
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group D
Number of subjects: 120
Study: 15312105

Group type: EXPERIMENTAL
Intervention: Oscillating/rotating powered toothbrush
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 40
Study: 10906914

Group type: EXPERIMENTAL
Intervention: Comprehensive massage therapy (n = 25)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Soft-tissue manipulation only (n = 25)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Remedial exercise with posture education only (n = 22)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sham laser therapy (n = 26)
Number of subjects: 98
Study: 9217890

Group type: EXPERIMENTAL
Intervention: Insulin infusion (3.5 mU/min) for 180 min in protocol I
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Insulin infusion (100 mU/min) in hand veins in protocol III
Number of subjects: 22

Group type: COMPARATOR
Intervention: Noradrenaline infusion (0.025, 0.01 and 0.4 microgram/min) at baseline, 90 and 180 min after insulin in protocol I
Number of subjects: 22

Group type: COMPARATOR
Intervention: Noradrenaline infusion (1.7-55 ng/min) at baseline and at 90 and 180 min in protocol II
Number of subjects: 22
Study: 8377448

Group type: EXPERIMENTAL
Intervention: Modified BFM-protocol (ALL REZ I/88) with alternating courses of polychemotherapy including intermediate dose methotrexate (1 g/m2 in 36 hours) and maintenance treatment with daily oral thioguanine and biweekly IV MTX.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Modified BFM-protocol (ALL REZ I/88)
Number of subjects: 55
Study: 3017033

Group type: EXPERIMENTAL
Intervention: Angiotensin II (AII) infusion (5 ng/kg/min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Angiotensin II (AII) infusion (5 ng/kg/min) with o-CRH injection (100 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham infusion with o-CRH injection (100 micrograms)
Number of subjects: 16
Study: 31810893

Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy (sRT)
Number of subjects: 1301
Study: 28931344

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine (SSD)-coated ureteral stents
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-coated ureteral stents
Number of subjects: 126
Study: 26383882

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 59
Study: 24951981

Group type: EXPERIMENTAL
Intervention: High-oleic peanuts (HOP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Conventional peanuts (CVP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control biscuits (CT)
Number of subjects: 71
Study: 21499794

Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART)
Number of subjects: 1563
Study: 20163872

Group type: EXPERIMENTAL
Intervention: Laser-induced chorioretinal venous anastomosis (L-CRA)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 113
Study: 18234324

Group type: EXPERIMENTAL
Intervention: Preventive counseling for mammography
Number of subjects: 3557

Group type: EXPERIMENTAL
Intervention: Preventive counseling for smoking
Number of subjects: 3557

Group type: EXPERIMENTAL
Intervention: Preventive counseling for diet
Number of subjects: 3557

Group type: EXPERIMENTAL
Intervention: Preventive counseling for sun protection
Number of subjects: 3557

Group type: EXPERIMENTAL
Intervention: More thorough counseling across all behaviors
Number of subjects: 3557

Group type: EXPERIMENTAL
Intervention: Prior counseling
Number of subjects: 3557
Study: 16117980

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexamethasone 16 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 80
Study: 14566347

Group type: EXPERIMENTAL
Intervention: Pyridoxine‐metoclopramide combination therapy
Number of subjects: 174

Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 174

Group type: COMPARATOR
Intervention: Promethazine
Number of subjects: 174
Study: 10364869

Group type: EXPERIMENTAL
Intervention: Tramadol and ondansetron
Number of subjects: 4

Group type: COMPARATOR
Intervention: Fentanyl and ondansetron
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tramadol and metoclopramide
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Fentanyl and metoclopramide
Number of subjects: 4
Study: 8558221

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 administered over 1 hour every 21 days
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2
Number of subjects: 37
Study: 1992912

Group type: EXPERIMENTAL
Intervention: Beta-interferon (IFN), ACNU, and Radiation
Number of subjects: 120

Group type: COMPARATOR
Intervention: ACNU and Radiation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Beta-interferon (IFN) therapy
Number of subjects: 120
Study: 6441010

Group type: EXPERIMENTAL
Intervention: 20 mg of intravenous metoclopramide administered 10 min prior to nasal insertion of a weighed feeding tube
Number of subjects: 10

Group type: COMPARATOR
Intervention: No premedication (Control)
Number of subjects: 10
Study: 30720004

Group type: EXPERIMENTAL
Intervention: SignaturePFS-CG (combination of clinical factors and COX-2/C-MET/KRAS expression status)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: SignatureOS-CG (combination of clinical factors and COX-2/C-MET/KRAS expression status)
Number of subjects: 578
Study: 29432125

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intensive medical diabetes and weight management (IMWM)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall quality of life
Number of subjects: 38
Study: 27123881

Group type: EXPERIMENTAL
Intervention: Embedded vocabulary and comprehension lessons during storybook reading
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard storybook reading without embedded lessons
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Embedded vocabulary and comprehension lessons
Number of subjects: 195
Study: 25182660

Group type: EXPERIMENTAL
Intervention: Adjunctive dipyridamole 75 mg twice daily
Number of subjects: 91

Group type: COMPARATOR
Intervention: Double-dose clopidogrel 150 mg daily
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups (DIP and DOUBLE)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: DIP group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: DOUBLE group
Number of subjects: 91
Study: 22596208

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18973887

Group type: EXPERIMENTAL
Intervention: Micro‐TESE (microdissection testicular sperm extraction) followed by intracytoplasmic sperm injection
Number of subjects: 792
Study: 16799799

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg twice daily for 12 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15023828

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 401
Study: 12487201

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with commercial beef extracts
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with fresh beef
Number of subjects: 34

Group type: COMPARATOR
Intervention: Literature review on skin prick tests for cow's milk
Number of subjects: 34
Study: 9500626

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 205
Study: 7716316

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Barium swallow
Number of subjects: 178
Study: 2664817

Group type: EXPERIMENTAL
Intervention: Augmentin (1.2 g intravenously 3-times daily for a mean of 6.6 days, then 375 mg orally for a further 6.4 days)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard therapy (1 g cefazoline intravenously 4-times daily plus 500 mg metronidazole intravenously 3-times daily for 7 days, then 500 mg cefadroxil orally 4-times daily for a mean of 6.6 days)
Number of subjects: 104
Study: 124721

Group type: EXPERIMENTAL
Intervention: Immediate reinforcement
Number of subjects: 44

Group type: COMPARATOR
Intervention: End-of-session reinforcement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Noncontingent reinforcement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Delayed reinforcement
Number of subjects: 44
Study: 31833150

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 126291

Group type: EXPERIMENTAL
Intervention: Cannabis use and depression genetic correlation
Number of subjects: 126291

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores for cannabis use and depression
Number of subjects: 126291

Group type: EXPERIMENTAL
Intervention: Two-sample Mendelian randomization analyses
Number of subjects: 126291
Study: 31724363

Group type: EXPERIMENTAL
Intervention: Interaction teaching mode integrated with virtual anatomy platform
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional practical teaching mode
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 29275583

Group type: EXPERIMENTAL
Intervention: Oxycodone (0.2 mg/kg) combined with dexmedetomidine (loading dose of 0.5 μg/kg for 10 minutes and continuous infusion of 0.2 μg·kg(‐1)·h(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl (2 μg/kg) combined with dexmedetomidine
Number of subjects: 60
Study: 25171115

Group type: EXPERIMENTAL
Intervention: LARS procedure
Number of subjects: 41

Group type: COMPARATOR
Intervention: MBG procedure
Number of subjects: 41
Study: 23919441

Group type: EXPERIMENTAL
Intervention: Coarse concentrated ambient particles (CAP) exposure for 2 hours
Number of subjects: 32

Group type: COMPARATOR
Intervention: Filtered air (FA) exposure for 2 hours
Number of subjects: 32
Study: 21701083

Group type: EXPERIMENTAL
Intervention: EPA plus statin (1,800 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Statin-only
Number of subjects: 50
Study: 18307781

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training programme (4 times a week for 8 weeks, initial intensity 65% VO2 peak)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training programme
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (maintained current physical activity level)
Number of subjects: 20
Study: 16930364

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (160 mg daily dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: donepezil (5 mg daily dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0